Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective

Paules CI, Marston HD, Fauci AS (2020) Coronavirus infections-more than just the common cold. JAMA 323(8):707–708. https://doi.org/10.1001/jama.2020.0757 Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W, Hao P (2020) Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 63(3):457–460. https://doi.org/10.1007/s11427-020-1637-5 Ramphul K, Mejias SG (2020) Coronavirus disease: a review of a new threat to public health. Cureus 12(3):e7276. https://doi.org/10.7759/cureus.7276 Elfiky AA (2021) SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective. J Biomol Struct Dyn 39(9):3204–3212. https://doi.org/10.1080/07391102.2020.1761882 Hui DS, E IA, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, McHugh TD, Memish ZA, Drosten C, Zumla A, Petersen E (2020) The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infectious diseases : IJID : official Publication Int Society for Infectious Dis 91:264–266. https://doi.org/10.1016/j.ijid.2020.01.009 Salata C, Calistri A, Parolin C, Palu G (2019) Coronaviruses: a paradigm of new emerging zoonotic diseases. Pathog Dis. https://doi.org/10.1093/femspd/ftaa006 Sohag AAM, Hannan MA, Rahman S, Hossain M, Hasan M, Khan MK, Khatun A, Dash R, Uddin MJ (2020) Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: a comprehensive review. Drug Dev Res. https://doi.org/10.1002/ddr.21709 Ashour HM, Elkhatib WF, Rahman MM, Elshabrawy HA (2020) Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens (Basel, Switzerland) 9 (3). doi:https://doi.org/10.3390/pathogens9030186 Kumar Y, Singh H, Patel CN (2020) In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. J Infect Public Health 13(9):1210–1223. https://doi.org/10.1016/j.jiph.2020.06.016 Hilgenfeld R (2014) From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 281(18):4085–4096. https://doi.org/10.1111/febs.12936 Mondal P, Natesh J, Abdul Salam AA, Thiyagarajan S, Meeran SM (2020) Traditional medicinal plants against replication, maturation and transmission targets of SARS-CoV-2: computational investigation. J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2020.1842246 Maldonado E, Tao D, Mackey K (2020) Antithrombotic therapies in COVID-19 disease: a systematic review. J Gen Intern Med 35(9):2698–2706. https://doi.org/10.1007/s11606-020-05906-y Monteleone G, Sarzi-Puttini PC, Ardizzone S (2020) Preventing COVID-19-induced pneumonia with anticytokine therapy. Lancet Rheumatol 2(5):e255–e256. https://doi.org/10.1016/S2665-9913(20)30092-8 Giani M, Seminati D, Lucchini A, Foti G, Pagni F (2020) Exuberant plasmocytosis in bronchoalveolar lavage specimen of the first patient requiring extracorporeal membrane oxygenation for SARS-CoV-2 in Europe. J Thoracic Oncol: official Publication International Association for the Study of Lung Cancer 15(5):e65–e66. https://doi.org/10.1016/j.jtho.2020.03.008 Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 191:145–147. https://doi.org/10.1016/j.thromres.2020.04.013 Kow CS, Hasan SS (2021) Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta-analysis. J Thromb Thrombolysis 52(1):124–129. https://doi.org/10.1007/s11239-021-02436-0 Corrochano M, Acosta-Isaac R, Mojal S, Miqueleiz S, Rodriguez D, Quijada-Manuitt MA, Fraga E, Castillo-Ocana M, Amaro-Hosey K, Albiol N, Soria JM, Antonijoan RM, Souto JC (2021) Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19. J Thromb Thrombolysis. https://doi.org/10.1007/s11239-021-02507-2 Mycroft-West C, Su D, Elli S, Li Y, Guimond S, Miller G, Turnbull J, Yates E, Guerrini M, Fernig D, Lima M, Skidmore M (2020) The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding. BioRxiv. https://doi.org/10.1101/2020.02.29.971093 Mahmud S, Elfiky AA, Amin A, Mohanto SC, Rahman ME, Acharjee UK, Saleh MA (2021) Targeting SARS-CoV-2 nonstructural protein 15 endoribonuclease: an in silico perspective. Futur Virol 16(7):467–474. https://doi.org/10.2217/fvl-2020-0233 Gyebi GA, Elfiky AA, Ogunyemi OM, Ibrahim IM, Adegunloye AP, Adebayo JO, Olaiya CO, Ocheje JO, Fabusiwa MM (2021) Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum. Comput Biol Med 136:104671. https://doi.org/10.1016/j.compbiomed.2021.104671 Sonousi A, Mahran HA, Ibrahim IM, Ibrahim MN, Elfiky AA, Elshemey WM (2021) Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective. Pharmacol Rep. https://doi.org/10.1007/s43440-021-00300-9 Elfiky AA, Ibrahim IM, Amin FG, Ismail AM, Elshemey WM 2021 COVID-19 and Cell Stress. In: Rezaei N (ed) Coronavirus Disease - COVID-19. Springer International Publishing, Cham, pp 169–178. doi:https://doi.org/10.1007/978-3-030-63761-3_10 Kupferschmidt K, Cohen J (2020) Race to find COVID-19 treatments accelerates. Science 367(6485):1412–1413. https://doi.org/10.1126/science.367.6485.1412 Abosheasha MA, El-Gowily AH (2021) Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 M(pro) and spike protein: drug repurposing approach. Drug Dev Res 82(2):217–229. https://doi.org/10.1002/ddr.21743 Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, Han L, He J, He S, Shoemaker BA, Wang J, Yu B, Zhang J, Bryant SH (2016) PubChem substance and compound databases. Nucleic Acids Res 44(D1):D1202-1213. https://doi.org/10.1093/nar/gkv951 2.4.1 V The PyMOL Molecular Graphics System, Version 2.4.1 Schrödinger, LLC. Huang J, MacKerell AD Jr (2013) CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. J Comput Chem 34(25):2135–2145. https://doi.org/10.1002/jcc.23354 Mark P, Nilsson L (2001) Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. J Phys Chem A 105(43):9954–9960 Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graphics 14(1):33–38. https://doi.org/10.1016/0263-7855(96)00018-5 Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kale L, Schulten K (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26(16):1781–1802. https://doi.org/10.1002/jcc.20289 Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605–1612 Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455–461. https://doi.org/10.1002/jcc.21334 Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785–2791. https://doi.org/10.1002/jcc.21256 Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M (2015) PLIP: fully automated protein–ligand interaction profiler. Nucleic Acids Res 43(W1):W443–W447 Khambholja K, Asudani D (2020) Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence. Travel Med Infect Dis 35:101710. https://doi.org/10.1016/j.tmaid.2020.101710 Elfiky AA (2020) Corrigendum to "Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARSCoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study" [Life Sci. 253 (2020) 117592]. Life Sci 258:118350. doi:https://doi.org/10.1016/j.lfs.2020.118350 Elfiky AA (2020) Reply to a letter to the editor. Life Sci 252:117715. https://doi.org/10.1016/j.lfs.2020.117715 Parvathaneni V, Gupta V (2020) Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges. Life Sci 259:118275. https://doi.org/10.1016/j.lfs.2020.118275 Baker NC, Lipinski MJ, Lhermusier T, Waksman R (2014) Overview of the 2014 food and drug administration cardiovascular and renal drugs advisory committee meeting about vorapaxar. Circulation 130(15):1287–1294. https://doi.org/10.1161/CIRCULATIONAHA.114.011471 group As, (2018) Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial. The lancet HIV 5(10):e553–e559. https://doi.org/10.1016/S2352-3018(18)30214-5 Teng R, Oliver S, Hayes MA, Butler K (2010) Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug metabolism and disposition: the biological fate of chemicals 38(9):1514–1521. https://doi.org/10.1124/dmd.110.032250 Dorsam RT, Kunapuli SP (2004) Central role of the P2Y12 receptor in platelet activation. J Clin Invest 113(3):340–345. https://doi.org/10.1172/JCI20986 Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J (2001) Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 19(4):369–386. https://doi.org/10.1111/j.1527-3466.2001.tb00076.x Elfiky AA, Ibrahim IM (2021) Host-cell recognition through GRP78 is enhanced in the new UK variant of SARS-CoV-2, in silico. J Infect 82(5):186–230. https://doi.org/10.1016/j.jinf.2021.01.015 Ibrahim MI, Elfiky AA, Elgohary AM (2021) Recognition through GRP78 is enhanced in the UK, South African, and Brazilian variants of SARS-CoV-2; An in silico perspective. Biochem Biophys Res Commun 562:89–93. https://doi.org/10.1016/j.bbrc.2021.05.058 Ibrahim IM, Abdelmalek DH, Elshahat ME, Elfiky AA (2020) COVID-19 spike-host cell receptor GRP78 binding site prediction. J Infect 80(5):554–562. https://doi.org/10.1016/j.jinf.2020.02.026 Elfiky AA (2020) SARS-CoV-2 spike-heat shock protein A5 (GRP78) recognition may be related to the immersed human coronaviruses. Front Pharmacol 11:577467. https://doi.org/10.3389/fphar.2020.577467 Elfiky AA, Ibrahim IM, Ismail AM, Elshemey WM (2021) A possible role for GRP78 in cross vaccination against COVID-19. J Infect 82(2):282–327. https://doi.org/10.1016/j.jinf.2020.09.004 Ismail AM, Elfiky AA (2020) SARS-CoV-2 spike behavior in situ: a Cryo-EM images for a better understanding of the COVID-19 pandemic. Signal Transduct Target Ther 5(1):252. https://doi.org/10.1038/s41392-020-00365-7